Human immunodeficiency virus-associated lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Kai Hübel(University Hospital Cologne), Andrew Davies, Silvia Montoto(Queen Mary University of London), Uta Brunnberg(Goethe University Frankfurt), Philipp Schommers(University of Cologne), Kate Cwynarski(University of Leeds), Marcus Hentrich(Red Cross Hospital), Mariana Bastos‐Oreiro(Hospital General Universitario Gregorio Marañón), M. J. Kersten(Amsterdam University Medical Centers), Bastian von Tresckow(University of Cologne), Alessandro Re(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Chiara Cattaneo(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), José‐Tomás Navarro(Universitat Autònoma de Barcelona), Mark Bower(Chelsea and Westminster Hospital), C. Buske(University Hospital Ulm), Caroline Besson(Bicêtre Hospital), M. Dreyling(LMU Klinikum), Josep‐María Ribera(Josep Carreras Leukaemia Research Institute), Igor Aurer(University Hospital Centre Zagreb), Christian Hoffmann(Infektionsmedizinisches Centrum Hamburg), Éric Oksenhendler(Hôpital Saint-Louis), Alessia Dalla Pria(Chelsea and Westminster Hospital), Simon Collins(Ghent University Hospital)
Cited by 11
Related Papers
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2010|1k